Welcome to Flow Pharma Inc.

Page Loading...

Menu

Powerful Immunotherapy

in a Stable Dry Powder

Delivery Methods

  • Anti-Virus – inhalation & intramuscular

  • Anti-Cancer – intranodal & intramuscular

No animal-sourced material. No live or dead virus. Does not rely on DNA or RNA transcription.

Rapidly Scalable


FLOVID-20

A New Vaccine for COVID-19. Administered by inhaler. FLOVID-20 is designed to treat and prevent all known variants by inhaler or by injection.

 

X-rays of COVID-19 exposed monkeys.

 

The left monkey was treated with inhaled FLOVID-20.

 
Under Development, FDA approval required.


New Hope for Treatment-Resistant Breast Cancer

FlowVax is an immunotherapy solution which targets a marker on many types of cancer cells which is not present on normal cells.

 

FlowVax has been shown to slow triple negative breast cancer growth in a mouse model.

 
Under Development, FDA approval required.


blob-1
blob-2
Our Mission

Flow Pharma is dedicated to immunotherapy innovation.

Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.


Product Portfolio


FLOVID-20

COVID-19, FLOVID-20

An inhaled or injected treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations.

FlowVax Ebola/Marburg

Ebola, Marburg

Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target these viruses, long-lasting infection prevention is attainable.

FlowVax BreastCA

Cancer

A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

FlowVax HPV

Cancer, HPV

A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.






Subscribe to Flow Pharma Updates